PERFADEX® and STEEN Solution™ approved in Russia
XVIVO Perfusion has obtained approval in Russia for marketing and clinical use of PERFADEX® and STEEN Solution™.
Russia’s Federal Service for Supervision on Health Care has approved PERFADEX® and STEEN Solution™ for lung transplantation. This means that PERFADEX® and STEEN Solution™ may be sold for clinical use in Russia.
Russia is not a large market today, but there is a great need for more lung transplants to be performed in the region. This registration allows clinics in Russia to gain access to PERFADEX®, which is adapted to lung preservation, and to be able to evaluate the quality of lungs using STEEN Solution™ and Ex Vivo Lung Perfusion (EVLP).
“The registration of PERFADEX® and STEEN Solution™ in Russia increases the accessibility of lung transplant products in this region and is a step in the right direction towards our vision that “No-one should need to die waiting for a new organ”. It is also in line with our long-term focus on future growth markets,” says Magnus Nilsson, CEO of XVIVO Perfusion.
February 16, 2016
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication on February 16, 2016 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ First North premier and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
Tags: